A community screening program for Helicobacter pylori saves money:: 10-year follow-up of a randomized controlled trial

被引:53
作者
Ford, AC
Forman, D
Bailey, AG
Axon, ATR
Moayyedi, P
机构
[1] McMaster Univ, Hlth Sci Ctr, Div Gastroenterol, Hamilton, ON, Canada
[2] Gen Infirm, Ctr Digest Dis, Leeds LS1 3EX, W Yorkshire, England
[3] Univ Leeds, Sch Med, Ctr Biostat & Epidemiol, Leeds LS2 9JT, W Yorkshire, England
关键词
D O I
10.1053/j.gastro.2005.09.016
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims: Population screening and treatment of Helicobacter pylori has been advocated as a means of reducing mortality from gastric cancer, as well as dyspepsia and dyspepsia-related resource use. Previous programs have failed to demonstrate a significant effect on mortality or resource use, but follow-up was only for 1 or 2 years. We aimed to determine the effect of screening for H pylori on dyspepsia and dyspepsia-related resource use over 10 years. Methods: H pylori-positive individuals, aged 40 - 49 years, enrolled in a community screening program, randomized to eradication therapy or placebo in 1994, were sent a validated dyspepsia questionnaire by mail 10 years later, and primary care records were reexamined. Consultation, referral, prescribing, and investigation data related to dyspepsia were extracted. United Kingdom costs were applied to derive total cost per person (1 pound = $1.8). Results: Of 2324 original participants, 1864 (80%) were traced and contacted. Of these, 1086 (47%) responded, and 919 (40%) agreed to a review of their primary care records. There was a 10-year mean saving in total dyspepsia-related costs of $117 per person (95% confidence interval [CI] = $114220, P = .03) with eradication therapy. Those symptomatic at baseline showed a nonsignificant trend toward resolution of symptoms at 10 years with eradication therapy (relative risk of remaining symptomatic, 0.89; 95% CI: 0.77 - 1.03). Conclusions: There were significant reductions in total dyspepsia-related health care costs. The savings made were greater than the initial cost of H pylori screening and treatment.
引用
收藏
页码:1910 / 1917
页数:8
相关论文
共 18 条
  • [1] *DEP HLTH, NHS REF COSTS 2002
  • [2] Ferlay J, 2004, GLOBOCAN 2002 CANC I
  • [3] Eradication therapy in Helicobacter pylori positive peptic ulcer disease:: Systematic review and economic analysis
    Ford, AC
    Delaney, BC
    Forman, D
    Moayyedi, P
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2004, 99 (09) : 1833 - 1855
  • [4] Ford Alex, 2003, Can J Gastroenterol, V17 Suppl B, p36B
  • [5] Validation of the short-form leeds dyspepsia questionnaire (SF-LDQ) in a community setting
    Fraser, A
    Qume, M
    Ford, A
    Redman, V
    Moayyedi, P
    Logan, R
    Duffy, J
    Wilson, S
    Delaney, BC
    [J]. GASTROENTEROLOGY, 2003, 124 (04) : A224 - A224
  • [6] SEROCONVERSION FOR HELICOBACTER-PYLORI
    KUIPERS, EJ
    PENA, AS
    VANKAMP, G
    UYTERLINDE, AM
    PALS, G
    PELS, NFM
    KURZPOHLMANN, E
    MEUWISSEN, SGM
    [J]. LANCET, 1993, 342 (8867) : 328 - 331
  • [7] The cost-effectiveness of population Helicobacter pylori screening and treatment:: a Markov model using economic data from a randomized controlled trial
    Mason, J
    Axon, ATR
    Forman, D
    Duffett, S
    Drummond, M
    Crocombe, W
    Feltbower, R
    Mason, S
    Brown, J
    Moayyedi, P
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2002, 16 (03) : 559 - 568
  • [8] How should Helicobacter pylori infection be diagnosed?
    Megraud, F
    [J]. GASTROENTEROLOGY, 1997, 113 (06) : S93 - S98
  • [9] Moayyedi P, 1998, ALIMENT PHARM THER, V12, P1257
  • [10] Effect of population screening and treatment for Helicobacter pylori on dyspepsia and quality of life in the community:: a randomised controlled trial
    Moayyedi, P
    Feltbower, R
    Brown, J
    Mason, S
    Mason, J
    Nathan, J
    Richards, IDG
    Dowell, AC
    Axon, ATR
    [J]. LANCET, 2000, 355 (9216) : 1665 - 1669